Cheng Xiao, Hou Zijun, Sun Jingbo, Huang Yan, Wang Lixin, Zhou Ziyi, Zhou Li-Hua, Cai Yefeng
Department of Neurology, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou 510120, China; The Second Institute of Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou 510120, China.
Department of Neurology, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou 510120, China; The Second Institute of Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou 510120, China; Medical Experimental Center, Nanyang Institute of Technology, Nanyang 473004, P.R. China.
J Ethnopharmacol. 2017 Feb 23;198:148-157. doi: 10.1016/j.jep.2017.01.004. Epub 2017 Jan 5.
Tongxinluo (TXL) is a multifunctional traditional Chinese medicine and has been widely used in the treatment of cardiovascular and cerebrovascular diseases. Numerous studies demonstrate that TXL is a novel neuroprotective drug, however, the mechanisms are largely unknown.
we aimed to demonstrate the protective effect of TXL on cerebral ischemia/reperfusion (I/R) injury and provide the evidence for the involvement of Connexin 43/Calpain II/ Bax/Caspase-3 pathway in TXL-mediated neuroprotection.
Focal cerebral I/R injury were induced by transient middle cerebral artery occlusion (MCAO, for 90min) in adult male Sprague-Dawley rats. We estimated the effects of TXL on I/R injury including neurological deficit assessment and cerebral infarct volume measurement via TTC staining, and detected the protein expression of Connexin 43 (Cx43) by western blot. Furthermore, after the intracerebroventricular injection of carbenoxolone (CBX, the inhibitor of Cx43) at 30min before MCAO surgery, Calpain II, Bax and cleaved Caspased-3 immunoreactivity in ischemic penumbra region was detected by immunofluorescent staining, and cell apoptosis was detected by TUNEL staining.
TXL treatment greatly improved neurological deficit and reduced the infarction volume compared to MCAO with buffer treatment (P<0.05), and TXL pre-post treatment showed better results than TXL pre-treatment. TXL pre-post treatment significantly up-regulated Cx43 protein expression at 3d, 7d and 14d post-injury compared to MCAO with buffer treatment (P<0.05). Meanwhile, the immunoreactivity of Calpain II, Bax and cleaved Caspase-3 in ischemic penumbra region was obviously decreased by TXL pre-post treatment compared to MCAO group (P<0.05). However, with the treatment of the Cx43 inhibitor, CBX, the down-regulated effect of TXL on Calpain II, Bax and cleaved Caspase-3 immunoreactivity was abolished (P<0.05). Moreover, the protective effect of TXL against neuron apoptosis in penumbra region was conteracted by CBX (P<0.05).
TXL could effectively protect against I/R injury and reduced cell death via Cx43/Calpain II/Bax/Caspase-3 pathway, which contribute to I/R injury prevention and therapy.
通心络(TXL)是一种多功能中药,已广泛应用于心血管和脑血管疾病的治疗。大量研究表明,TXL是一种新型神经保护药物,然而,其作用机制尚不清楚。
我们旨在证明TXL对脑缺血/再灌注(I/R)损伤的保护作用,并为连接蛋白43/钙蛋白酶II/Bax/半胱天冬酶-3通路参与TXL介导的神经保护作用提供证据。
采用成年雄性Sprague-Dawley大鼠大脑中动脉短暂闭塞(MCAO,90分钟)诱导局灶性脑I/R损伤。我们评估了TXL对I/R损伤的影响,包括通过TTC染色进行神经功能缺损评估和脑梗死体积测量,并通过蛋白质印迹法检测连接蛋白43(Cx43)的蛋白表达。此外,在MCAO手术前30分钟脑室内注射甘珀酸(CBX,Cx43抑制剂)后,通过免疫荧光染色检测缺血半暗带区域的钙蛋白酶II、Bax和裂解的半胱天冬酶-3免疫反应性,并通过TUNEL染色检测细胞凋亡。
与缓冲液处理的MCAO组相比,TXL治疗显著改善了神经功能缺损并减小了梗死体积(P<0.05),且TXL预处理后治疗组的效果优于TXL预处理组。与缓冲液处理的MCAO组相比,TXL预处理后治疗组在损伤后3天、7天和14天显著上调了Cx43蛋白表达(P<0.05)。同时,与MCAO组相比,TXL预处理后治疗组使缺血半暗带区域的钙蛋白酶II、Bax和裂解的半胱天冬酶-3免疫反应性明显降低(P<0.05)。然而,使用Cx43抑制剂CBX治疗后,TXL对钙蛋白酶II、Bax和裂解的半胱天冬酶-3免疫反应性的下调作用被消除(P<0.05)。此外,CBX抵消了TXL对半暗带区域神经元凋亡的保护作用(P<0.05)。
TXL可通过Cx43/钙蛋白酶II/Bax/半胱天冬酶-3通路有效保护免受I/R损伤并减少细胞死亡,这有助于I/R损伤的预防和治疗。